Irbesartán Almus

Irbesartan, the active ingredient in Irbesartán Almus, is a angiotensin II receptor blocker presented as an oral dosage form for oral use. It is employed to treat hypertension and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartán Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to control blood pressure and renal disease progression.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Diabetic nephropathy: slows the decline of renal function in patients with type 2 diabetes.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or mild weakness. - Upper respiratory tract infection symptoms. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Acute renal impairment or rise in serum creatinine. - Hyperkalemia, particularly in patients with renal dysfunction. - Hepatic injury presenting with jaundice or elevated liver enzymes.

Irbesartan should be used with clinical monitoring and patient education. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution and adjust dose if needed. - Pregnancy: avoid use; teratogenic risk is unknown. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines that affect renal function or electrolyte balance.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients. - Dual therapy with ACE inhibitors or other ARBs. - Potassium‑sparing diuretics (e.g., spironolactone) increasing hyperkalemia risk. - Lithium: may raise lithium serum levels. - High‑dose NSAIDs: can precipitate renal failure.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole) modestly increase irbesartan exposure.